[Newly developed drugs to improve bone strength].
Tottori, Japan. In Clin Calcium, Dec 2015
In addition, new drugs with new action mechanisms such as cathepsin K inhibitor or anti-sclerostin antibody are also being developed and it has been reported that they have good potential to increase bone mineral density.
Alveolar Soft Part Sarcoma.
Iowa City, United States. In Arch Pathol Lab Med, Nov 2015
Cathepsin K is a relatively recent immunohistochemical stain that can aid in the diagnosis.
Emerging Therapies for Osteoporosis.
Portland, United States. In Endocrinol Metab (seoul), Oct 2015
Inhibiting cathepsin K reduces bone resorption without decreasing the numbers of activities of osteoclasts, thereby preserving or promoting osteoblast function.
Osteoporosis: now and the future.
Dresden, Germany. In Lancet, 2011
The most promising novel treatments include: denosumab, a monoclonal antibody for receptor activator of NF-κB ligand, a key osteoclast cytokine; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation.